Munita, JoséAitken, SamuelMiller, WilliamPerez, FedericoRosa, RossanaShimose, LuisLichtenberger, PaolaAbbo, LilianJain, RupaliNigo, MasayukiWanger, AudreyAraos, RafaelTran, TrucAdachi, JavierRakita, RobertShelburne, SamuelBonomo, RobertArias, Cesar2017-08-302017-08-302017Clinical Infectious Diseases, Volume 65, Issue 1, 1 July 2017, Pages 158–161http://hdl.handle.net/11447/1619http://dx.doi.org/10.1093/cid/cix014A multicenter, retrospective study of patients infected with carbapenem-resistant Pseudomonas aeruginosa who were treated with ceftolozane/tazobactam was performed. Among 35 patients, pneumonia was the most common indication and treatment was successful in 26 (74%). Treatment failure was observed in all cases where isolates demonstrated ceftolozane-tazobactam minimum inhibitory concentrations ≥8 μg/mL.44en-USceftolozanecarbapenem resistantP. aeruginosamultidrug resistantArtículo